S5 Ep37: Sekeres Previews Potential Combination Strategies in HR-MDS

OncLive® On Air - En podcast av OncLive® On Air

Podcast artwork

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.

Visit the podcast's native language site